Загрузка...
Castrate Resistant Prostate Cancer: Post-Docetaxel Management
PURPOSE OF REVIEW: Prior to 2010, docetaxel was the only treatment shown to prolong survival in metastatic castrate resistant prostate cancer (CRPC). In the past three years several therapeutic agents have demonstrated survival improvements for CRPC after receipt of prior docetaxel, leading to multi...
Сохранить в:
| Опубликовано в: : | Curr Opin Urol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4486479/ https://ncbi.nlm.nih.gov/pubmed/23344012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOU.0b013e32835e2253 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|